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Abstract
Summary Still little is known about the manifestations of
osteogenesis imperfecta (OI) in adults. We therefore initiated
this study of bone mass, bone turnover and prevalence of
fractures in a large cohort of adult patients. We found a
surprising low prevalence (10%) of osteoporosis. These
patients, however, expressed the most severe disease.
Purpose To characterize bone mineral density, bone turn-
over, calcium metabolism and prevalence of fractures in a
large cohort of adults with osteogenesis imperfecta.
Methods One hundred fifty-four patients with adult OI
participated and 90 (age range 25–83) provided dual X-ray
absorptiometry (DXA) measurements. According to Sil-
lence classification criteria, 68 persons were classified as OI
type I, 9 as type III, 11 type IV and 2 were unclassified.
Fracture numbers were based on self-reporting. Biochem-
ical markers of bone turnover were measured and bone
mineral density (BMD) of the spine, femoral neck and total
body were determined by DXA.
Results Only 10% of adults with OI exhibited osteoporotic T
scores (T≤−2.5) but compared to patients with normal T
scores this subgroup had a threefold higher fracture risk (22
vs. 69). s-PTH, s-Ca and 25[OH] vitamin D were all normal.
Bone markers did not display major deviations from normal,
but patients with OI type III displayed higher resorption
marker levels than type I and IV. Multivariate regression
analysis showed that only gender and total body BMD were
significant determinants of fracture susceptibility, and the
differences for total body BMC, BMD and Z scores were
significant between the OI subtypes.
Conclusions In adult OI, DXA measurements only identified
fewpatientsasosteoporotic.Thesepatients,however,exhibited
a much higher fracture propensity. Due to deformities, low
body height and pre-existing fractures, DXA assessment is
complicated in this disease, and further studies are needed to
work out how to minimize the impact of these confounders.
Keywords Osteogenesis imperfecta.Adult.Bone mineral
density.Osteoporosis.Bone marker
Introduction
Osteogenesis imperfecta (OI) is the most common of the
genetic connective tissue disorders that primarily affect
bone. In the majority of patients with OI, the disease has
been linked to mutations in one of two genes coding for
collagen type I α chains (COL1A1 and COL1A2) [1], but
in some patients with the typical phenotypic characteristics
of OI, no such mutations were found. The most commonly
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and distinguishes four clinical subtypes of OI [2]. Over the
last years, however, several new subtypes have been added
to this classification [3–5].
Fractures after minimal trauma constitute the main
clinical feature of OI. In the past, OI was often regarded
as a form of osteoporosis. However, contrary to postmeno-
pausal osteoporosis, where loss of bone mass and structure
predominate, OI is characterized by increased bone fragility
due to defective matrix quality caused by defective type I
collagen [6, 7]. The fracture rate in OI is high in the
prepubertal years, declines in the post-pubertal years and
rises again after menopause in women and between 60 and
80 years of age in men [8–10]. In OI the regulation of
calcium metabolism is generally unperturbed with serum
levels of Ca, parathyroid hormone (PTH) and vitamin D
metabolites within the reference range in most patients [10–
12]. Some centres have however reported low vitamin D
levels in a significant proportion of patients [13].
While assessment of bone mineral density (BMD) by
dual X-ray absorptiometry (DXA) and bone turnover
markers have been used extensively in children, in
particular for the evaluation of medical treatment with
bisphosphonates [14–16], few data pertaining to these
variables have been reported in adults with OI [17, 18].
However, questions about osteoporosis are often brought up
by the patients with OI when they reach their adult life, and
many of them worry about the clinical consequences of a
combination of OI and age-related bone loss. In subjects
with OI, no consensus on bone turnover levels has been
reached. Bone turnover has been described as both normal
to low [19–21] or increased [18, 22–24].
In order to better describe the prevalence of fractures, bone
mineral density, bone turnover and calcium metabolism in
adults with OI, we initiated this study in a large cohort of
Norwegian patients with adult OI. The diagnosis of OI was
based on clinical characteristics according to Sillence classi-
fication and family history. By measuring BMD we also
wanted to study how common osteoporosis, as defined by
WHO criteria [25], is in adult patients with OI, and whether
BMD was related to Sillence type, and prevalence of
fractures.
Methods
Material
The present study was part of a larger study describing an
adult population with OI in Norway, aged 25 years and
older [26]. This age limit was chosen as it is anticipated that
the peak bone mass has been obtained at 25 years of age in
persons with a normal skeleton [27]. Adults with OI
registered at The National Resource Centre for Rare
Disorders (TRS) were invited to participate in the study
(n=154) of which 97 agreed to participate. The prevalence
of clinically diagnosed OI in a Caucasian population has
been reported to be about 5 of 100,000 [28], and in
Norway, this should correspond to a total number of
persons with OI in the range of 200–300. On a voluntary
basis, TRS has registered 259 persons with OI, but there are
however no studies of the completeness of this registry. The
type of OI was classified using the Sillence criteria [2], and
95 patients who fulfilled the criteria of OI type I (75
persons), type III (9 persons) or type IV (11 persons) were
included [26]. Two persons were unclassified and are not
included in all analyses. The study was approved by the
regional medical research ethics committee. Each of the
participants gave their written consent.
Data collection
Fracture history
All participants underwent a structured interview concerning
medical history and a clinical examination. The total number
of fractures was self-reported by the patients during the
interview. No further ascertainment of fractures was done.
Uncertainties related to recall of the total number of fractures
were also registered. This uncertainty was divided into four
categories: (1) certain—the exact number of fractures, 2)
slightly uncertain—variation of five fractures, (3) uncertain—
variation of more than five fractures and (4) very uncertain.
Bone mineral density
BMD (g/cm²) of the lumbar vertebrae L2–L4 in the anterior–
posterior projection, total hip and the total body skeletonwere
determined by DXA (Lunar DPX-1; Lunar, WI, USA). As
bone mass is sex and age specific, the individual BMD values
wereconverted intoZ and Tscores based on reference values
of the manufacturer. Earlier analyses demonstrated that this
normal range was comparable to values derived from a
Norwegian cohort [29]. The coefficients of variation (CV%)
for BMD in persons without OI in our laboratory were 1.1%
for the lumbar spine, 1.0% for the femoral neck, 1.4% for the
total hip and 0.9% for the total body. The CV% for bone
mineral content (BMC) was 2.0% for the lumbar spine and
0.8% for the total body.
Assessment of calcium metabolism and biochemical
markers of bone turnover
Blood tests were drawn and second void morning urine
were sampled in the fasting state between 8 and 9 o'clock in
the morning and analyzed as routine tests at the Hormone
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of the participants were using supplement of calcium and
vitamin D (Table 1).
Bone turnover markers
Serum levels of osteocalcin were measured by luminoim-
munoassay (BRAHMS Diagnostica GMBH, Berlin, Ger-
many), C-terminal telopeptide of type I collagen generated
by metalloproteinases (1CTP) by radioimmunoassay (Orion
Diagnostica, Espoo, Finland) and bone-specific alkaline
phosphatase (bALP) by enzyme activity measurement
(Metra Biosystems Inc., CA, USA). The urine concen-
tration of N- telopeptides type I collagen (NTX) were
measured by enzyme immunoassay (Ostex, Seattle, WA,
USA) and corrected for urine creatinine concentration.
Calcium metabolism
Serum levels of 25-hydroxyvitamin D (25(OH)D) were
measured by radioimmunoassay (DiaSorin, Stillwater, MN,
USA), and serum levels of intact PTH by chemiluminoim-
munometric assay (DPC, Los Angeles, CA, USA). Ionized
calcium levels were measured using the 634 Ca²+/pH
analyzer from Ciba Corning.
Statistical methods
Descriptive statistics were reported for the different types of
OI according to Sillence.
Due to the strongly skewed distributions of the total
number of fractures, linear regression analysis was
performed after the log transformation. Linear regression
analysis was also performed to look at possible associ-
ations between the total number of fractures, OI type,
and age (divided into the following groups: all women,
women <50 years, women ≥50 years, all men). Compar-
isons of the total number of fractures in women ≥50 years
and <50 years were performed by one-way ANOVA.
Comparisons of the bone markers data across groups
were done by one-way ANOVA, and corresponding post
hoc tests with Bonferroni correction. P values ≤0.05 were
considered statistically significant. All analyses were
carried out using the Statistical Package for the Social
Sciences, SPSS, version 15.0.
Results
Demographic and ambulatory characteristics of the study
populationarelistedinTable1. Seventeen persons (16 females
and 1 male) were using bisphosphonates and/or hormone
replacement therapy. There were no significant differences in
anti-osteoporosis treatment between OI subtypes. Twelve
persons had suffered new fractures or undergone orthopaedic
procedures during the last year. Routine biochemistry
exhibited few abnormalities: One patient with revealed
increased serum glucose (15.9 mmol/l); one suppression of
TSH (FT4=18.50 pmol/l) and two males exhibited increased
TSH (FT4=14.5 and 14.9 pmol/l). All patients showed
normal kidney function with serum creatinine below
110 umol/l, except for one elderly patient (83 years) with a
value of 140 umol/l.
Prevalence and localisation of fractures
Table 2 shows the median numbers of total fractures for the
study population and the median numbers of total fractures
related to gender and OI type. The degree of uncertainty
expressed by the patients regarding the total number of
fractures sustained in any given individual showed that
about 86% of the participants were quite certain about the
number of fractures they had sustained (variation of five
fractures or less). However, those who had sustained a high
number of fractures expressed a higher degree of uncertainty
(>±5 fractures).
All OI patients OI type 1 OI type 3 OI type 4 Unclassified
N 97 75 9 11 2
Sex (male/female) 41/56 28/47 3/6 9/2 1/1
Age (mean±SD) 44±12 45±13 35±7 47±7 49
Weight (kg), (mean±SD) 66±17 69±13 36±14 70 (12) 69
Height (cm), (mean±SD) 156±20
a 163±10 106±13 157±17 157
Ambulation using wheelchair 19 (20%) 7 (9%) 9 (100%) 3 (27%) 0
Drug use
HRT/bisphosphonates 17 (18%) 13 (17%) 1 (11%) 2 (18%) 1 (50%)
Kalsium/vitamin D 24 (25%) 21 (28%) 0 3 (27%) 0
Fractures or orthopaedic operations
last 12 months
12 (12%) 9 (12%) 0 2 (18%) 1 (50%)
Table 1 Patient characteristics
HRT hormone replacement
therapy
aMedian value was 161.5 cm
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long bones of the arms and legs or small bones of hands
and feet. Thirty-two percent reported vertebral fractures,
however 51% of the participants had never been tested and
did not know whether they had suffered vertebral fractures
or not. Fifty-four percent reported fractures at other
locations as ribs, clavicle, mandible/maxilla, nose, pelvis
and scapula. There were no significant differences in
number of prevalent fractures between those who used
bisphosphonates and those who did not.
Determinants of fracture susceptibility
Univariate regression analyses revealed significant associ-
ations between OI type, sex, total body BMC and BMD
(total body and total hip) and number of fractures. After
multiple regression analyses did gender (males) and total
body BMD remained significant predictors for the number
of fractures, while the effects of the other predictors became
nonsignificant.
No significant correlation between the total number of
fractures and women's age (p=0.133), women <50 years of
age (p=0.968), women ≥50 years (p=0.061), men's age
(p=0.226) or the age in OI type I (p=0.110) was
demonstrable. These analyses were not performed in groups
with OI type III and IV due to the low number of patients in
these groups.
Bone mineral density
Seven participants were not measured by DXA (2 were
pregnant, 1 could not be examined in the supine position,
4 did not want to participate in this part of the study),
leaving 90 for DXA assessment. However, DXA of the
spine and hip were confounded by considerable problems
in technical analyses due to pathology such as metal
implants and deformities. For this reason, 48 DXA
measurements of the spine and 22 DXA measurements
of the total hip were not included in the results. During
assessment of lumbar spine BMD values, vertebrae with
obvious compression fracture were excluded. As the
software program excludes areas with metal implants,
patients with such implants were not excluded from the
total body measurements.
Summary data of bone mass (BMC) and BMD for the
study population, and for the different OI types, are
presented in Table 3. We found significant differences
between Sillence type III and type I and IV with respect to
total body BMC (p<0.001), total body BMD (p<0.001)
and total body BMD Z score (p=0.02). Skeletal pathologies
in patients with OI type III prevented us from getting any
measurements of the spine and the hip in this group. Type
IV revealed a significantly lower L2–L4 Z score (p=0.01)
than type I, but no difference in total hip Z score was found.
Osteopenia and osteoporosis
Total body BMD T scores showed a wide variation, ranging
between −4.70 and +1.90. For the different subtypes, the
range did not differ significantly. Mean T scores for the
different subtypes ranged between −0.61 for type I and −2.74
for type III in the total body. No significant differences
between types of OI were found at the hip (no OI type III
included) (Table 4). We found significant differences for the
total body BMD T score, between OI type I and type III and
between type IV and type III (p<0.001), with type III
exhibiting the lowest values. No significant differences were
found between type I and type IV (p=1.0).
Table 2 Total number of all prevalent fractures with the patients categorized by gender and by Sillence type and divided into 5-year age groups
Age N, 39 Men median
(range)
N, 55 Women median
(range)
N, 94 Total median
(range)
N, 74 OI type I median
(range)
N, 7 OI type III
median (range)
N, 11 OI type IV
median (range)
25–30 2 28 (20–35) 10 12 (2–50) 12 17 (2–50) 9 10 (2–35) 3 28 (25–50)
30–35 6 36 (3–250) 6 10 (1–15) 12 13 (1–250) 10 10 (1–37) 1 250 1 57
35–40 7 10 (2–30) 9 15 (5–40) 16 14 (2–40) 13 13 (5–40) 1 25 1 28
40–45 5 60 (17–300) 5 5 (1–100) 10 38 (1–300) 7 17 (1–61) 2 75 (50–100) 1 300
45–50 5 10 (4–170) 6 11 (4–20) 11 10 (4–170) 9 10 (4–170) 2 10 (4–16)
50–55 9 20 (7–40) 6 12 (1–20) 15 13 (1–40) 9 11 (1–40) 6 21 (13–25)
55–60 2 20 (20–20) 5 14 (4–100) 7 15 (4–100) 6 17 (4–100)
50–65 1 55 5 30 (13–74) 6 35 (13–74) 6 35 (13–74)
65–70 1 4 2 32 (9–55) 3 9 (4–55) 3 9 (4–55)
70+ 1 7 1 15 2 11 (7–15) 2 11 (7–15)
Information about total number of fractures is missing in three participants, and two participants are not typed, N=92
N number of patients
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between −1.0 and −2.5) and osteoporosis (T score ≤−2.5)
[25], 27 (30%) of the participants fulfilled the criteria for
osteopenia and 9 (10%) for osteoporosis on total body
BMD (Table 4) .B a s e do nt o t a lh i pB M DT scores, 34
(50%) of the participants fulfilled the criteria for osteope-
nia and 10 (21%) for osteoporosis.
Calcium metabolism
s-PTH, s-Ca and 25(OH) vitamin D levels were normal in
all OI subtypes (Table 5). Sixteen participants exhibited 25
(OH) vitamin D values <50 nmol/l, but only one revealed
signs of secondary hyperparathyroidism (s-PTH 8.5 pmol/
l). Persons with OI type III displayed significantly lower
values for 25 vitamin (OH) D (p=0.05) than persons with
OI type I and IV.
Bone turnover
Patients using bisphosphonates and/or hormone replacement
therapy (HRT, n=17) were excluded from the following
calculations. Patients who had sustained fractures and/or had
orthopaedic operations the last 12 months (n=12) did not
display significant deviations pertaining to bone markers and
bone mineral density measurements and were therefore not
excluded from these analyses. Figure 1 shows serum levels
for two markers of bone formation (osteocalcin and bALP)
and three markers of bone resorption [1CTP, deoxypyridino-
line crosslinks (DPYD) and NTX]. Generally, patients with
OI type III displayed slightly lower formation maker levels.
1CTP was significantly higher in OI type III than in OI
type I (p=0.02) and DPYD was significantly higher in OI
type III than in OI type IV (p=0.05). NTX did not show
significant differences across the groups.
Table 3 Bone mineral density and bone mineral content of the total body, total hip and lumbar vertebrae L2–L4 (number of observations in
brackets)
Total (mean±SD) Type I (mean±SD) Type III (mean±SD) Type IV (mean±SD) P value
Bone mineral density and mass
a, total body
Number of patients 90 68 9 11
BMC total body, kg 2.26±0.66 2.40±0.50 0.99±0.32 2.38±0.50 <0.001
BMD total body, g/cm² 1.10±0.11 1.11±0.09 0.93±0.09 1.14±0.10 <0.001
Z, BMD total body −0.39±1.03 −0.29±1.02 −1.31±0.92 −0.45±0.89 0.02
Bone mineral density and mass (L2–L4) and total hip without pathology
BMC L2–L4, g 37.28±8.86 (52) 37.60±8.78 (47) –
c 34.27±10.07 (5) 0.43
BMC total hip, g 27.47±7.69 (68)
b 26.97±7.68 (61) –
c 30.20±8.74 (6) 0.90
BMD L2–L4, g/cm² 0.93±0.14 (52) 0.95±0.14 (47) –
c 0.82±0.12 (5) 0.05
BMD total hip, g/cm² 0.85±0.17 (68)
b 0.84±0.16 (61) –
c 0.89±0.22 (6) 0.51
Z, BMD L2–L4 −1.99±1.09 (52) −1.87±1.06 (47) –
c −3.19±0.66 (5) 0.01
Z, BMD total hip −1.15±1.22 (68)
b −1.55±1.28 (61) –
c −1.12±1.77 (6) 0.32
aSeven participants were not investigated with DXA
bTwo were unclassified
cAll patients with OI type III had considerable deformities in both spine and hip and could not be analyzed
N BMD T score
[mean±SD (range)]
Osteopenia T score=−1.0>
−2.5, number (%)
Osteoporosis T
score≤−2.5, number (%)
From total body
Total 90
a −0.83±1.30 (−4.70–1.90) 27 (30) 9 (10)
OI type I 68 −0.61±1.11 (−3.70–1.90) 19 (28) 3 (5)
OI type III 9 −2.74±1.30 (−4.70–0.90) 2 (22) 6 (67)
OI type IV 11 −0.73±1.11 (−2.10−1.10) 5 (46) 0
From total hip
Total 68
b −1.52±1.33 (−4.60–1.70) 34 (50) 10 (21)
OI type I 61 −1.55±1.28 (−4.60−1.70) 30 (47) 15 (23)
OI type IV 6 −1.55±1.72 (−3.80–0.80) 5 (63) 1 (13)
Table 4 Osteopenia and osteo-
porosis after the criteria of the
World Health Organization
aTwo were unclassified
bOne was unclassified
All patients with OI type III had
pathology in the hip that made
the measurements impossible for
technical reasons
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The aim of this study was to ascertain number of fractures,
bone density, bone turnover and calcium metabolism in an
adult population with OI. Only 17 persons in our study
population were using bisphosphonates and/or HRT (13
were using bisphosphonates), which gave us the opportu-
nity to investigate bone mineral density and metabolism in
adults with OI unaffected by pharmaceuticals affecting
bone metabolism. Increased knowledge in this field is
needed to create adequate guidelines for treatment and
follow-up of OI in adult life.
Several papers have reported that fractures in women with
OI tend to occur mostly before puberty, decrease through
adulthood and then increase after menopause [8, 30]. Paterson
et al. found that the fracture rate rose after menopause in
women and remained low after adolescence in men. This
increase in fractures in postmenopausal women was consid-
ered a result of OI combined with age-related bone loss. In
our study we were unable to corroborate this finding. We
found no correlation between age and the total number of
fractures, neither in women nor in men. Although we have
not had the possibility to measure the age-specific incidence
rate of clinical fractures, we think that the reported prevalence
data indicate that there is no increase in rate in the elderly
women and men. There were no significant differences in the
total number of fractures between women before and after
50 years of age, as would have been expected if the age-
related bone loss had been superimposed on the effect of OI.
Our hypothesis explaining this phenomenon is that the poor
matrix quality of OI bone due to the collagen defects
overrides other age- and menopause-dependent changes in
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36 Arch Osteoporos (2011) 6:31–38bone mass and structure. Concerning OI type and total
number of fractures, our study showed no correlation between
total number of fractures and age in OI type I. The numbers
of OI type III and IV were too small to make this analysis.
With respect to the localization of fractures, our findings
are in accordance with the literature [9]. Long bones of the
arms and legs, and small bones of the hands and feet were
most frequently broken. As more than half of the patients
never had a spinal X-ray examination, the estimation of
spine fracture prevalence in this cohort was impossible.
Bone mineral density and osteoporosis
Few studies have examined the role of BMD measurements
in the diagnosis or as a risk factor for fracture in adult OI.
Although BMD is not essential for establishing the
diagnosis of OI, it appears to be an indicator of disease
severity and may be predictive of long-term functional
outcome [31]. As in osteoporosis, the low BMD is probably
a major risk factor for further fractures. However, few adult
patients with OI have been investigated using BMD. In our
study more than 50% of the participants had previously
never had a BMD measurement, and none of them had been
subjected to regular DXA follow-up.
Several studies have measured BMD in children [14–16]
and in adults [10, 17] with OI. Most of them have measured
the lumbar spine and/or the hip. In our cohort, especially
for OI types III and IV, measurements from the lumbar
spine and the hip could not be analyzed due to considerable
deformities. Adults with OI often have scoliosis which
makes any form of spine measurement difficult [32].
Another important issue is the lack of overall agreement
on how to adjust BMC for body size, thereby creating
BMD values, in adults with OI. In multivariate analysis,
gender and total body BMD were significant determinants
of fracture susceptibility, no significant impact of OI type,
total hip BMD and total body BMC was demonstrable. As
total body BMD is technically easier to perform in OI
patients than spine and hip, total body BMD probably
should be used as the preferred BMD estimate in patients
with OI.
Persons with OI are often described as osteoporotic, but
BMD values in OI have also been reported as normal [32].
In the absence of consensus on how to characterize possible
osteoporosis in adults with OI, we chose to use established
criteria for osteoporosis. Using the WHO criteria on total
body BMD, about 30% of the total OI population had
osteopenia, and 10% were osteoporotic. Remarkably, only
4% with OI type I were osteoporotic (T score <−2.5) based
on total body BMD, while 25% were classified as
osteoporotic using total hip BMD.
Serum calcium has been reported as generally normal in
patients with OI [11, 12]. Serum 25-hydroxyvitamin D may
be low [13]. In our study we found normal S-PTH, s-Ca
and vitamin D levels in serum. Subjects with OI type III, all
wheelchair users, however, displayed significantly lower
values for 25(OH)D than persons with OI type I and IV.
Low values for vitamin D will tend to increase the bone
turnover due to secondary hyperparathyreoidism, and we
found that all resorption markers were increased in OI type
III compared to OI types I and IV, although PTH was not
increased in OI type III. However, these results should be
evaluated with caution, as we did not include a control
group, but only relied on the reference ranges of the
laboratory. Previous reports give no clear direction in terms
of bone turnover markers. Reduced, normal and increased
levels have been reported [18–24].
There are some limitations in this study. The study
population included about two thirds of the registered
Norwegian adult OI population, but as OI is a rare disease,
the sample size was still small, especially in the groups of
OI type III and IV. This makes it difficult to compare the
groups. We do not have the possibility to perform collagen
analysis in our country, and the diagnosis of OI was
therefore based on clinical examination and family history.
Because the total number of fractures was based on
information from the patients, and not possible to verify,
this information was uncertain. However, the degree of
uncertainty was clearly associated with the total number of
fractures. Those who expressed the highest uncertainty had
the highest number of fractures.
Conclusions
In conclusion, total body BMD is probably the best
estimate in adults with OI. However, due to deformities,
low body height and pre-existing fractures, DXA assess-
ment is complicated in this disease, and further studies are
needed to work out how to minimize the impact of these
confounders. Our analyses of bone mineral density indicate
that only 10% of patients displayed osteoporotic T scores,
further supporting the notion that bone fragility in OI
mainly stems from defective collagen structure. These
patients, however, exhibited a much higher fracture
propensity than patients with normal T scores. The levels
of bone turnover markers were normal in the vast majority
of patients. However, in adults with OI type III, bone
turnover tended to be increased and osteoporosis more
prevalent.
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